India Rejects Patents For GSK Diabetes Drug, Pfizer Anti-Cholesterol
This article was originally published in PharmAsia News
Executive Summary
India's patent authority turned down protection for GlaxoSmithKline's diabetes and Pfizer's cholesterol drugs, exposing them to generic competition. The Delhi Patent Office said GSK did not make a case that its Avandia (rosiglitazone) was more efficacious than a previous version, freeing generics by Dr. Reddy's Laboratories, Sun Pharma and Torrent Pharma. The office also rejected Pfizer's Caduet, which combines its Norvasc (amlodipine) and Lipitor (atorvastatin). Torrent raised objections about a Caduet patent and the Patent Office agreed. (Click here for more